GELNIQUE 3%
PeakNDATRANSDERMALGEL, METERED
Approved
Dec 2011
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 13h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
GELNIQUE 3% is a transdermal gel formulation of oxybutynin, an anticholinergic small molecule approved in 2011 for overactive bladder. The metered-dose gel is applied topically and absorbed systemically to reduce urinary urgency, frequency, and incontinence. It represents an alternative delivery route to oral anticholinergics, designed to improve tolerability and compliance.
Peak
At peak lifecycle with moderate competitive pressure (30%), suggesting stable but not expanding commercial infrastructure.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on GELNIQUE 3% at peak lifecycle offers stable career opportunity in a mature, defensible market segment. Roles emphasize market maintenance, prescriber education, and competitive differentiation rather than launch or development activities.
Brand ManagerField Sales Representative
Worked on GELNIQUE 3% at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.